About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Thailand Scraps Patent Override on Cancer Drug With Novartis

by Medindia Content Team on February 2, 2008 at 4:09 PM
Font : A-A+

Thailand Scraps Patent Override on Cancer Drug With Novartis

Thailand will not override a patent on leukaemia drug Glivec after its maker, Swiss giant Novartis, agreed to give the medicine to most patients for free, an official said Friday.

The move was a last-minute victory for the outgoing military-backed government, which was at loggerheads with Western pharmaceutical firms over so-called compulsory licenses, which temporarily suspend patent protections.

Advertisement

The government already overrode patents for popular heart drug Plavix and two key AIDS medicines -- Kaletra and Efavirenz -- and has threatened to expand its generic programmes to include cancer drugs, including Glivec.

But Novartis has agreed to give Glivec to Thai patients for free, said Suchart Chongtrasert, a senior official at the Food and Drug Administration and a member of Thailand's generic drug negotiation team.
Advertisement

"The company agreed to give the medicine to Thai patients for free. We are satisfied with the outcome. With the company's proposal, there is no need to do CL," Suchart said, referring to compulsory licenses.

Thai cancer patients with an annual household income of less than 1.7 million baht (51,000 dollars) are eligible to receive free Glivec, he said.

Currently, Glivec, which is also known as Imatinib, costs 130,000 baht (4,000 dollars) per patient per month, the ministry said.

As Thailand's newly-elected Prime Minister Samak Sundaravej is set to form his cabinet early next week, Suchart said he hoped the new government would continue to press ahead with generic drug programmes.

"I hope the new government will work hard on CL. The issue is very important for Thais," Suchart said.

Activists have hailed Thailand's drive for copycat drugs as a "beacon" for other developing nations seeking to provide treatments to the poor.

But pharmaceutical giants have derided it as an infringement on their intellectual property rights, warning that lost profits would make it harder to finance research for medical innovations.

A Bangkok office for Novartis could not be reached for comment.

Source: AFP
SRM/L
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Get Involved and Stand Up for Human Rights on Human Rights Day 2022
Coronary Artery Bypass Grafting
Macronutrients Calculator for Weight Loss
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Oncology Drug Delivery Systems Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant Immune Checkpoint Inhibitors for Cancer Treatment Non-Communicable Diseases 

Most Popular on Medindia

Post-Nasal Drip Iron Intake Calculator Blood Donation - Recipients Hearing Loss Calculator Calculate Ideal Weight for Infants Turmeric Powder - Health Benefits, Uses & Side Effects Sinopril (2mg) (Lacidipine) Selfie Addiction Calculator Accident and Trauma Care Pregnancy Confirmation Calculator
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Thailand Scraps Patent Override on Cancer Drug With Novartis Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests